The downregulation of hsa-miR-143-3p, also suggested as a potential AD biomarker in other reviews, is believed to contribute to AD by promoting tau phosphorylation and increasing APP levels, leading to Aβ accumulation [107]. This evidence concerns the gene MAPT and Alzheimer disease.